Diabetes and obesity drugs also lead to large reductions in adverse cardiovascular events, and the benefits aren’t just down ...

Ozempic (R) was approved by Health Canada in 2018. Ozempic (R) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control.

Patients with oHCM experience significant variation in cardiovascular events, health care resource use, and costs across age, sex, race, and US region.

LISBON, Portugal—Patients who undergo a cardiac prehabilitation prior to elective surgery or procedures via a smartphone app have a lower incidence of major adverse cardiovascular events (MACE) ...

"Underprescribing in Black patients could be partially because they were severely underrepresented in the major cardiovascular outcome trials and subsequent meta-analyses showed only a neutral effect.

Novo Nordisk announced today that Health Canada has approved Ozempic® (semaglutide injection) to reduce the risk of major adverse cardiovascular (CV) events ...